The current trend in soft tissue neoplasia is to define tumors based on their underlying genomic alterations. Moreover, clinicians increasingly request testing for “actionable” mutations which may allow for targeted therapy. However, not every institution may have access to specific molecular tests for rare or ultra rare soft tissue tumors, and the definition of “actionable” in regards to many mutations seen in sarcoma is dubious at best. This presentation will discuss diagnostic and theragnostic targets in sarcoma, and discuss pros, cons, and workarounds for molecular diagnostic testing in this context.